Effects of membrane lipid and fluidity modifications on HIV-1 infectibility of primate lymphocytes in vitro. NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Effects of membrane lipid and fluidity modifications on HIV-1 infectibility of primate lymphocytes in vitro.

Biosci Rep. 1990 Jun;10(3):263-70. Unique Identifier : AIDSLINE MED/91028157
Zimmer JP; Lehr HA; Hubner C; Lindner SG; Ramsperger R; Claussen M; Kohlschutter A; Schmitz H; Department of Virology, Bernhard Nocht Institute for Nautical and; Tropical Diseases, Hamburg, West Germany.

Abstract: Although most non-human primates, except the chimpanzee and the gibbon in vivo are not infectible by HIV-1, lymphocytes of several of these species can be infected by HIV-1 in vitro. In order to investigate whether the in vitro infectibility of primate lymphocytes might be attributed to plasma membrane adaptation processes or to serum factors, we compared HIV-1 infectibility of cultivated peripheral blood lymphocytes of macaques and of baboons on day one and on day ten of cultivation. These data were correlated to plasma membrane lipid composition and membrane fluidity. We found a correlation between increased HIV-1 in vitro infectibility and changes in plasma membrane lipid composition resulting in decreased membrane fluidity of cultured primate lymphocytes.
Keywords: Animal HIV-1/*PHYSIOLOGY In Vitro Lymphocytes/*MICROBIOLOGY/PHYSIOLOGY Macaca radiata Membrane Fluidity/PHYSIOLOGY Membrane Fusion/PHYSIOLOGY Membrane Lipids/*METABOLISM Papio Receptors, HIV/PHYSIOLOGY Support, Non-U.S. Gov't Virus Replication/PHYSIOLOGY JOURNAL ARTICLEKWDanimalhiv-1/KWDphysiologyinvitrolymphocytes/KWDmicrobiology/physiologymacacaradiatamembranefluidity/physiologymembranefusion/physiologymembranelipids/KWDmetabolismpapioreceptors,hiv/physiologysupport,non-uKWDsKWDgov'tvirusreplication/physiologyjournalarticle
910228
M9120667

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .